technology, we developed a unique class of T-cell engager, namely ProTIA (Protease Triggered Immune Activator) that exploits the protease overexpression characteristics of the tumor microenvironment. Previously, we reported that anti-human-EpCAM/anti-human-CD3 ProTIA demonstrated strong in vivo ...